Status: Recruiting
Study to Assess Safety and Efficacy of Treating Symptomatic, Ischemic, Chronic Congestive Heart Failure Patients with an LVEF of ≤40% with Fresh, Uncultured, Autologous, Adipose-derived Regenerative Cells Isolated from Lipoaspirate.
To investigate patients suffering from iHF and a LVEF of equal or less than 40% despite best medical treatment safety and efficacy of a single retrograde intra-cardiac venous (i.cv.) injection of UA-ADRCs isolated from lipoaspirate at the point of care, using the Transpose® RT / Matrase System (InGeneron, Houston, TX, USA) through an over-the- wire, small balloon catheter, advanced through the coronary si-nus and located within a coronary vein at the site of inter-est, versus patients on best medical treatment.
Participants needed: 36
Trial details
Phase: Phase 2Age: 21-80Biological sex: AllType: InterventionalSponsor: Ralf RothoerlUpdated: Dec 3, 2024Locations: 1
Eligibility criteria
Have documented coronary artery disease with evidence of myocardial injury, LV d... [+5]
Indication for standard-of-care surgery (including valve surgery, placement of L... [+32]